Physician profile
Rex D Evans
NPI 1215927512
$2,756.23
in general payments reported to CMS, 2019-2025
25 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $580 · 2023: $563 · 2024: $315 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $439.03 | 2021-2025 | |
| Pfizer INC. | $287.20 | 2021-2023 | |
| Lilly USA, LLC | $185.61 | 2021-2025 | Mounjaro, Jardiance |
| Boston Scientific Corporation | $147.16 | 2021-2023 | Exalt Model D |
| Glaxosmithkline, LLC. | $121.44 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $116.53 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $90.51 | 2021 | |
| Amarin Pharma, INC. | $86.57 | 2021-2022 | |
| Abbott Laboratories | $80.58 | 2023-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $73.01 | 2022 | |
| Amgen INC. | $70.66 | 2021-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $54.05 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.09 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $45.53 | 2021-2025 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $44.44 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.56 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $24.90 | 2023 | Uptravi, Opsumit |
| Otsuka America Pharmaceutical, INC. | $23.54 | 2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $22.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.47 | 2021 | |
| Sunovion Pharmaceuticals INC. | $14.59 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.84 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.79 | 2024 | Voquezna |
| Biogen, INC. | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rex Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.